Saltar al contenido
Merck

A protocol for efficient CRISPR-Cas9-mediated knock-in in colorectal cancer patient-derived organoids.

STAR protocols (2021-09-30)
Takuya Okamoto, Yasuko Natsume, Hitomi Yamanaka, Mayuko Fukuda, Ryoji Yao
RESUMEN

Patient-derived organoids (PDOs) recapitulate the cellular heterogeneity of the original colorectal tumor tissue. Here, we describe a protocol to generate genetically modified PDOs to investigate cancer stem cells. This protocol uses the CRISPR-Cas9 system to knock-in the IRES-EGFP-P2A-iCaspase9 cassette into the 3' UTR of the potential cancer stem cell marker gene, which allows us to investigate their potential for self-replication and pluripotency. We describe the procedure for generating mutant PDOs and their application for stem cell research. For complete details on the generation and use of this protocol, please refer to Okamoto et al. Okamoto et al. (2021).

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
N-Acetyl-L-cysteine, BioReagent, suitable for cell culture
Sigma-Aldrich
Y-27632 dihydrochloride, ≥98% (HPLC)
Sigma-Aldrich
Puromycin dihydrochloride, Ready Made Solution, from Streptomyces alboniger, 10 mg/mL in H2O, suitable for cell culture
Sigma-Aldrich
[Leu15]-Gastrin I human, ≥95% (HPLC)
Sigma-Aldrich
Neomycin trisulfate salt hydrate, powder
Roche
Kit de síntesis de sonda DIG para PCR, sufficient for 25 reaction (50 μL final reaction volume)
Roche
DIG Luminescent Detection Kit, sufficient for 50 blots (10 cm x 10 cm each), kit of 1 (5 components), suitable for hybridization